News

Fidaxomicin had a 13.5% higher rate of 4-week sustained response compared to vancomycin and 13.2% higher rate for 8-week sustained response.

Patients with ≥1 CDI-related admissions versus no CDI admissions experienced higher rates of 6-month readmission and annual cost across all hospitalizations.

AXS-05 also showed superiority to placebo in safety.

A greater prevalence of hidradenitis suppurativa, psoriasis, folliculitis, and hirsutism in pediatric patients with obesity compared to the general pediatric population.

SER-109 engraftment was durable through week 24 and significantly higher than placebo at all time points for all comparisons.

Most adverse events reported were mild or moderate and found in a similar percentage of patients regardless of treatment cohort.

New data suggests there is no connection between ustekinumab and the risk of malignancies.

While the long-term efficacy and safety of the biologic has been investigated in, few studies have been based on real life experience.

There are several companies preparing new treatments for recurrent C difficile infections.

There are several potential treatments on the horizon for C difficile infections.

The meta-analysis included more than 11,000 patients with between 8 and 9 years of mean follow-up periods.

Screening and early-life interventions for these patients may prevent cardiometabolic outcomes, according to investigators.

Primary care provider Dr. Gerald Smetana shares key information and resources to give PCPs all they need know about prescribing outpatient therapies for COVID-19.

The public perception of marijuana has shifted significantly, and Dr. Timothy Fong addresses how to keep up with progressive research and what risk factors still need to be better understood.

EoE expert Dr. Marc Rothenberg says it's a relief to know that the FDA has finally approved a drug for EoE.

Oral doses of 3 Janus kinase inhibitors show the therapies out-performed placebo in all outcomes measured in patients with moderate-to-severe AD.

Despite most adverse events of special interest being deemed mild to moderately severe in nature, these types of events have been increasingly reported in real-world practice.

Despite this, close gynecological monitoring of pregnant women with PR was still recommended.

RBX2660, an investigational microbiota-based live biotherapeutic for the treatment of C difficile, safely and effectively reduced recurrent C diff for 6 months.

Gina Poe, PhD, discusses the potential role of beta blockers in treating psychiatric illness-related sleep, as well as the specific benefit of melatonin.

NIDA research director Carlos Blanco-Jerez, MD, PhD, reviews how stigma, language barriers and digital health create disparate outcomes in mentally-ill Hispanic patients.

Lois Choi-Kain, MD, MEd, discusses her field's interest in improving the modern diagnosis and evidenced-based treatment of personality disorders.

The UCLA-based investigator discusses the unique impact of PTSD on patients' sleep stages, and how they can limit their insomnia.

With limitations on fidaxomicin at their facility, a hospital looked at vancomycin usage to determine if they needed to align with the new IDSA/SHEA CDI treatment guideline.

Keratosis pilaris has often been associated with AD and filaggrin loss-of-function mutations, the latter of which are frequent in Europe with an approximate prevalence of 7%

At DDW 2022, Dr. Sands highlights the positive findings from the LUCENT-1 study on the efficacy and safety of mirikizumab.

Patients treated with ustekinumab are not at an increased risk of malignancies.

Investigators led by Dr. Bowie deemed it necessary to establish “transparent classification” of topical corticosteroids in the pursuit of stronger and more reliable dermatologic outcomes and treatments.